Media headlines about Deciphera Pharmaceuticals (NASDAQ:DCPH) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Deciphera Pharmaceuticals earned a daily sentiment score of 0.00 on Accern’s scale. Accern also gave news headlines about the company an impact score of 48.0259003694413 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Deciphera Pharmaceuticals stock opened at $24.13 on Tuesday. The firm has a market capitalization of $833.43 and a price-to-earnings ratio of -8.07. Deciphera Pharmaceuticals has a 12 month low of $15.15 and a 12 month high of $29.98. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.35 and a quick ratio of 14.35.

How to Become a New Pot Stock Millionaire

Deciphera Pharmaceuticals (NASDAQ:DCPH) last posted its earnings results on Wednesday, March 28th. The company reported ($0.62) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.19). equities research analysts forecast that Deciphera Pharmaceuticals will post -2.36 earnings per share for the current year.

A number of research analysts have issued reports on the company. BidaskClub upgraded Deciphera Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 12th. Zacks Investment Research lowered Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, January 8th. Finally, B. Riley began coverage on Deciphera Pharmaceuticals in a report on Friday, February 16th. They issued a “buy” rating and a $43.00 target price for the company. One analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the stock. Deciphera Pharmaceuticals has an average rating of “Buy” and a consensus price target of $41.14.

COPYRIGHT VIOLATION NOTICE: “Deciphera Pharmaceuticals (DCPH) Given Daily Coverage Optimism Rating of 0.00” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company develops DCC-2618, a pan-KIT and pan-PDGFRa inhibitor for the treatment of gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors.

Insider Buying and Selling by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with's FREE daily email newsletter.